ΑΙhub.org
 

#ICML2022 invited talk round-up 2: estimating causal effects and drug discovery and development


by
10 August 2022



share this:
DNA

In this post, we summarise the final two invited talks from the International Conference on Machine Learning (ICML 2022). These presentations covered estimation and inference for causal effects, and machine learning for drug discovery and development.

Synthetic control methods and difference-in-differences – Guido Imbens

Guido’s talk covered the topic of estimation and inference for causal effects in panel data settings, in particular focussing on synthetic control methods and difference-in-difference methods. These methods are very popular in the empirical literature in economics, but many questions remain concerning causal effects in these settings. There has been a lot of recent theoretical work trying to improve practices in this field.

Guido devoted most of the presentation to explaining how one might go about estimating the causal effect of some treatment, with a specific focus on binary treatments. The particular setting that he looked at is one where we observe multiple units (these units could be individuals, states, countries, or companies, for example) repeatedly over time as a particular treatment is administered. In some problems, the number of units is large and they are observed over a short time period. In others, the number of units is small, but they are observed over a long time period.

screenshot of guido's talkScreenshot from Guido’s talk.

Firstly, Guido focussed on the case where there are two observations for each unit and time period: one observation is the outcome, and the other observation is the binary treatment. The units are split into a treatment group and a control group, and we are interested in the average difference between the treated group and the control group. Guido gave some examples of where these methods have been used in the past to evaluate the effect of treatments. These include California smoking regulation, the re-unification of Germany, and minimum wage changes.

Lots of different methods have been used for estimating average treatment effects, including matching, inverse propensity score weighting, and double robust methods. Guido took the audience through some of the regression techniques used, looking at some different scenarios. He talked about the importance of selecting the method that is appropriate the application in question, and looking for combinations of different methods to find the most effective.

To close, Guido left the audience with one question for future research: how can we systematically combine experimental and observational data to answer questions that neither can directly answer?

To find out more, you can see the slides from Guido’s talk here.

Design for inference in drug discovery and development – Aviv Regev

To introduce her talk, Aviv took us on a whistle-stop tour of the last 40 years of medical history, in which many technological developments, combined with biological insights, have enabled medical breakthroughs. These include recombinant DNA technologies which led to protein drugs, and therapeutic antibodies which have brought many important medicines.

Aviv’s research mission is to use machine learning to try to make fundamental scientific discoveries and to use these insights to help in the development of therapeutics for patients. One promising area for research is human genetics. Over the course of the last 15 years, analysis of the variation in the genomes of hundreds of thousands of individuals has identified about 100,000 regions in the human genome where differences in the DNA sequence are associated with the risk of developing a range of different diseases. Looking at this from the point-of-view of drug discovery, this analysis gives researchers a starting point as to where to begin in the search for potential new drugs.

Screenshot from Aviv's talkScreenshot from Aviv’s talk.

In her talk, Aviv shared some examples of how machine learning and experiments come together in target discovery, drug discovery, and clinical development. She primarily focussed on the first of these: target discovery.

Most of the genetic variants in our genome associated with common complex diseases are within regions that regulate gene expression. The question is: how can we progress from an understanding of the initial changes in the regulatory region to an understanding of the impact of those changes on genes and cells (i.e. the effect on our bodies)? Aviv outlined the method that she and her team use to try to answer this question. They start with a biological system (for example, the tissue or cell that plays an important role in the disease in question), they perturb it experimentally, then they measure the effect using high-resolution techniques. From these data, they train a machine learning model and query it for a hypothesis. They then use that hypothesis to design the next experiment. The process is repeated to design further experiments.

Aviv and her team have developed a deep transformer neural network model that takes any arbitrary DNA sequence and predicts the level of gene expression. The goal is that, with such a model, they can predict what a new variant does. This the first step in moving from human genetics towards a new drug. Training the model required a huge number of examples of regulatory sequences and the associated measured expression – more than currently exist. To get round this problem, the team used randomly generated DNA sequences for extra training examples. Because the model generalises extremely well, they could use it as an oracle to design sequences for gene expression engineering.

In the final part of her talk, Aviv touched on the next part of the process: drug discovery. She and her team have investigated combining machine learning models and experiments for studying antibodies, small molecules and RNA vaccines.

You can find out more on her website.



tags: ,


Lucy Smith is Senior Managing Editor for AIhub.
Lucy Smith is Senior Managing Editor for AIhub.

            AUAI is supported by:



Subscribe to AIhub newsletter on substack



Related posts :

Controllable AI and the power of local knowledge: an interview with Carmen Amo Alonso

  17 Nov 2026
How can we build AI systems that do what we want them to do? Control theory can help.

Data-driven re-discovery of 2D materials

  16 Nov 2026
With the help of AI, researchers have found previously overlooked occurrences of the 2D materials MXenes in older databases.

Tech-savvy STEM students prone to letting AI do their thinking for them

  13 Nov 2026
How can students break their dependence on AI tools?

An invisible word of the day: watermarking assignment prompts to detect copy-pasted chatbot answers

  12 Nov 2026
SteganoPrompt lets educators embed an invisible but openly announced instruction in an assignment prompt.

AI100 longitudinal study examines how AI has entered the mainstream

  10 Nov 2026
Published every five years, the report is compiled by experts in the field.
AI pioneers

Thinking big – from constraint programming to the Holy Grail: an interview with Gene Freuder

  10 Nov 2026
In our latest instalment of AI Pioneers, we speak to Gene Freuder on the field of constraint programming, neurosymbolic and generative AI approaches in AI, and the bigger picture of computer science.

How attackers persuade AI agents to break the rules

  09 Nov 2026
As AI assistants evolve into AI agents, a study has found that the biggest safety risks in their use may not come from single malicious prompts, but from carefully orchestrated conversations.

Interview with Minji Park: humans in the loop to keep language models up to date

  06 Nov 2026
Human-AI co-inference through a shared editable state.


↑


AUAI is supported by:







Subscribe to AIhub newsletter on substack




 















©2026.05 - Association for the Understanding of Artificial Intelligence